A good outcome for the CHILD-INNOVAC project: Successful test in humans of a nasal vaccine against pertussis

The CHILD-INNOVAC European research programme, coordinated by Inserm, has enabled the development of an innovative vaccine that can be administered intranasally, to combat pertussis, which has shown a resurgence in developed countries in recent years. The research consortium, headed by Camille Locht, Director of the Centre for Infection and Immunity of Lille, today published promising results from Phase I clinical trials of the vaccine in human subjects in the online journal PLOS ONE. Read more